March 1, 2016
The FDA has approved a new once-daily drug regimen for the treatment of HIV. Odefsey, by Gilead Sciences, is composed of emtricitabine (200 mg), rilpivirine (25 mg) and tenofovir alafenamide (25 mg).
Odefsey contains the same drugs as Complera, except it replaces disoproxil fumarate (TDF) with tenofovir alafenamide (TAF). TAF is a prodrug of tenofovir that delivers high antiviral efficacy at a much lower dose than TDF. The lower dose of TAF that can be used to treat HIV means that it has a better safety profile -- and is easier on the kidneys and bones -- than TDF.
"As people are living longer with HIV, there is an increasing need to develop new treatments that are tolerable and help address long-term health for patients," said John C. Martin, Ph.D., chairman and chief executive officer of Gilead Sciences. "Odefsey's safety, efficacy and tolerability profile offers a new treatment option to support the needs of a range of patients and represents Gilead's commitment to innovation in the field of HIV."
This excerpt was cross-posted with the permission of BETAblog.org. Read the full article.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.